Putting Drug Prices on TV Will Cause Unnecessary Patient Panic – Pacific Research Institute

Putting Drug Prices on TV Will Cause Unnecessary Patient Panic

Last month, the Trump administration proposed several reforms to drive down prescription drug prices.

One measure would force pharmaceutical companies to mention the sticker prices of their medicines in television advertisements. The new mandate covers all prescriptions drugs reimbursed by Medicare or Medicaid that cost more than $35 a month.

The administration hopes this change will empower patients to choose more affordable drugs and embarrass companies into reducing their prices. But the rule won’t achieve those goals.

Instead, it would mislead customers into thinking drug prices are higher than they actually are. It could deter patients from asking doctors about medicines that would improve, or even save, their lives.

The rule would require advertisements to announce drugs’ “wholesale acquisition cost.” That’s the sticker price manufacturers set when they introduce products to market.

Pharmaceutical companies don’t actually receive this amount; it’s merely the starting point for pricing negotiations with health insurers, pharmacy benefit managers, and other middlemen in the supply chain. These negotiations result in substantial discounts. On average, manufacturers rebate about one-third of a drug’s sticker price back to payers. Often, discounts can cut 60 percent or more off the sticker price. Last year alone, manufacturers offered more than $150 billion in discounts and rebates.

Manufacturer discounts wouldn’t be reflected in TV ads. So the price patients see on their screens would be substantially higher than the true, discounted price.

Even that discounted price doesn’t represent what people pay at the pharmacy counter. Patients’ out-of-pocket spending depends on their insurance plans, which detail their co-pays, co-insurance, deductibles, and so on. It’s entirely possible that a patient could pay just a few dollars for a drug with a sticker price of hundreds, or even thousands, of dollars.

Forcing drug companies to announce unrepresentative list prices isn’t merely unhelpful — it could actively harm patients’ health. Beyond making patients more anxious about the price of their drugs, sticker shock could prevent people from taking necessary medications.

As drug prices go up, patients are far less likely to adhere to their prescriptions. Doubling patient co-pays reduces adherence by as much as 45 percent. If patients mistakenly believe they’re going to spend a small fortune, they may never inquire about medicines that could keep them healthy.

The Trump administration is right that patients ought to be better informed about drug costs. But there’s a better way to offer that transparency.

Major drug manufacturers have proposed directing TV viewers to websites that provide detailed pricing breakdowns about advertised drugs. These sites include practical data such as average out-of-pocket expenses. Online, manufacturers have the space to provide essential details and more accurate price estimations that can’t be squished into 30-second commercials.

The Trump administration’s new advertising proposal is well-intentioned — but it’s likely to backfire and scare people away from needed medications. Officials would be wise to shelve the rule.

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top